Skip to main content
锦波生物 logo

锦波生物 — Investor Relations & Filings

Ticker · 920982 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 391 across all filing types
Latest filing 2025-06-25 Capital/Financing Update
Country CN China
Listing Beijing Stock Exchange 920982

About 锦波生物

https://www.sxjbswyy.com/

Shanxi Jinbo Bio-Pharmaceutical Co., Ltd. specializes in the research, development, and manufacturing of functional proteins through synthetic biology. The company is recognized for its industrialization of recombinant humanized collagen, specifically Type III collagen with a stable triple helix structure. Its core business encompasses the production of medical-grade biomaterials, functional skincare products, and medical devices used in aesthetics, wound healing, and gynecological health. By utilizing advanced protein engineering, the company provides biocompatible solutions designed for tissue repair and anti-aging applications. Its technical focus remains on the structural optimization and large-scale production of high-purity recombinant proteins to meet clinical and consumer health demands.

Recent filings

Filing Released Lang Actions
2025年度向特定对象发行股票募集说明书（草案）.pdf
Capital/Financing Update Classification · 95% confidence The document is titled as a "募集说明书（草案）" which translates to "Prospectus (Draft)" for a specific stock issuance by Shanxi Jinbo Bio-Pharmaceutical Co., Ltd. It details the company's plan for a 2025 targeted stock issuance to specific investors, including the background, purpose, pricing, share allocation, shareholder structure, regulatory approvals needed, and risk factors. The document is comprehensive and includes financial data, company background, and detailed explanations of the issuance plan. It is not a simple announcement but a full prospectus document related to capital raising. This fits the definition of a Capital/Financing Update (CAP) as it provides detailed information on fundraising activities and capital structure changes. It is not an Annual Report, Earnings Release, or other report types. The length (15,000 characters) and content confirm it is a full document, not just an announcement or certification. Therefore, the correct classification is CAP with high confidence.
2025-06-25 Chinese
关于股东签订股份转让协议及向特定对象发行股票暨权益变动的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding a shareholder agreement for share transfer and a private placement of shares to specific investors, including strategic cooperation details and shareholding changes. It includes specifics about share quantities, prices, lock-up periods, and regulatory approvals required. The document is not a financial report, earnings release, or management discussion but rather a formal announcement of a capital/financing event involving share transfer and issuance. It does not contain financial statements or earnings data but focuses on the transaction details and shareholder structure changes. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length and detail confirm it is not a brief announcement or a simple regulatory filing but a substantive update on financing activities.
2025-06-25 Chinese
中信证券股份有限公司关于山西锦波生物医药股份有限公司2025年度向特定对象发行股票涉及关联交易的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed verification opinion from CITIC Securities regarding a specific transaction: the 2025 issuance of shares to a particular investor involving related party transactions. It includes extensive information about the transaction, the related party, approval procedures, pricing, impact on the company, and regulatory compliance. The document is not a full annual or interim financial report, nor is it a simple announcement or certification. It focuses on a capital raising event involving issuance of shares to a strategic investor and related party transaction disclosures. This fits the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document length (8412 characters) and content confirm it is a substantive report on the financing event, not merely an announcement or regulatory filing. Therefore, the correct classification is CAP with high confidence.
2025-06-25 Chinese
简式权益变动报告书（养生堂有限公司、久视管理咨询（杭州）合伙企业（有限合伙））
Major Shareholding Notification Classification · 100% confidence The document is titled as a "简式权益变动报告书" which translates to a "Simplified Equity Change Report." It details the changes in shareholding of the company 山西锦波生物医药股份有限公司, including share transfers and issuance to specific investors. The document includes detailed information about the shareholders, shareholding percentages before and after the transaction, agreements related to share transfer and subscription, and strategic cooperation agreements. It references compliance with Chinese securities laws and Beijing Stock Exchange listing rules. The content is focused on reporting changes in significant share ownership and related agreements, not on financial results, management changes, or other report types. Therefore, this document fits the category of Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels crossing thresholds.
2025-06-25 Chinese
第四届监事会第七次会议决议公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the seventh meeting of the fourth Supervisory Board of Shanxi Jinbo Biopharmaceutical Co., Ltd. The content focuses on approval of proposals related to a 2025 private placement of shares to specific investors, including the issuance plan, pricing, number of shares, use of proceeds, and related agreements. It includes voting results and procedural details. The document is not a full financial report, audit report, or earnings release, but rather a formal announcement of board-level decisions and approvals related to capital raising activities. It is not a proxy statement or AGM materials, but a regulatory announcement of board resolutions concerning financing. Therefore, the best fitting category is Capital/Financing Update (CAP). The document length (7869 characters) and detailed content support this classification with high confidence.
2025-06-25 Chinese
关于召开2025年第二次临时股东会通知公告（提供网络投票）
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice for convening the 2025 second extraordinary general meeting (临时股东会) of Shanxi Jinbo Biopharmaceutical Co., Ltd. It includes information about the meeting date, voting methods (onsite and online), agenda items for shareholder approval, registration procedures, and proxy authorization forms. The content focuses on the announcement and procedural details of the shareholders' meeting rather than the results of voting or the meeting minutes. It does not contain financial statements or report data. The document length is 3757 characters, which is relatively short and consistent with a meeting notice. Therefore, this document is best classified as a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2025-06-25 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.